Key result
Micra leadless pacing cuts major complications ~51% versus conventional transvenous pacemakers.
Why the study?
Leadless pacing is rapidly expanding beyond conventional device contraindications to explore the potential benefit of avoiding long-term transvenous leads in any patient requiring pacing.
Effect estimate: HR 0.49 (95% CI 0.33-0.75)
Absolute Event Rate: 4% vs 7.4%
p-value: p=0.001
This review summarizes the current evidence, safety, performance, and future directions of leadless pacing devices across various patient populations.
May support Micra preference to lower complications; leaves open randomized confirmation before practice change.
Leadless pacing is a rapidly growing field. Initially designed to provide right ventricular pacing for those who were contraindicated for conventional devices, the technology is growing to explore the potential benefit of avoiding long-term transvenous leads in any patient who requires pacing. In this review, we first examine the safety and performance of leadless pacing devices. We then review the evidence for their use in special populations, such as patients with high risk of device infection, patients on haemodialysis, and patients with vasovagal syncope who represent a younger population who may wish to avoid transvenous pacing. We also summarise the evidence for leadless cardiac resynchronisation therapy and conduction system pacing and discuss the challenges of managing issues, such as system revisions, end of battery life and extractions. Finally, we discuss future directions in the field, such as completely leadless cardiac resynchronisation therapy-defibrillator devices and whether leadless pacing has the potential to become a first-line therapy in the near future.
No takes yet. Share an insight, caveat, or question.
Wijesuriya et al. (2023) conducted a review in Cardiac pacing indications. Leadless pacing (Micra) vs. Conventional transvenous pacemakers was evaluated on Major complications (HR 0.49, 95% CI 0.33-0.75, p=0.001). Leadless pacing with the Micra device significantly reduced major complications compared to conventional transvenous pacemakers (HR 0.49).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: